Research ArticleArticle
Open Access
Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic Arthritis
Proton Rahman, Christopher T. Ritchlin, Philip S. Helliwell, Wolf-Henning Boehncke, Philip J. Mease, Alice B. Gottlieb, Shelly Kafka, Alexa P. Kollmeier, Elizabeth C. Hsia, Xie L. Xu, May Shawi, Shihong Sheng, Prasheen Agarwal, Bei Zhou, Paraneedharan Ramachandran, Yanli Zhuang and Iain B. McInnes
The Journal of Rheumatology May 2021, jrheum.201532; DOI: https://doi.org/10.3899/jrheum.201532
Proton Rahman
This study was sponsored by Janssen Research & Development. P. Rahman, MD, Memorial University of Newfoundland, St. John's, Newfoundland, Canada; C.T. Ritchlin, MD, MPH, University of Rochester, Rochester, New York, USA; P.S. Helliwell, PhD, University of Leeds, Leeds, UK; W.H. Boehncke, MD, Geneva University Hospitals, Geneva, Switzerland; P.J. Mease, MD, Swedish Medical Center/Providence St Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A.B. Gottlieb, MD, PhD, Icahn Medical School at Mount Sinai, New York, New York, USA; S. Kafka, MD, Janssen Scientific Affairs, Horsham, Pennsylvania, USA; A.P. Kollmeier, MD, X.L. Xu, PhD, Janssen Research & Development, San Diego, California, USA; E.C. Hsia, MD, Janssen Research & Development, Spring House, Pennsylvania, USA, and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; M. Shawi, PhD, Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, Pennsylvania, USA; S. Sheng, PhD, P. Agarwal, PhD, B. Zhou, PhD, P. Ramachandran, MD, MPH, Y. Zhuang, PhD, Janssen Research & Development, Spring House, Pennsylvania, USA; I.B. McInnes, MD, PhD, University of Glasgow, Glasgow, UK. CTR has received research support from AbbVie, Amgen, and UCB, and consultant fees from AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB. PR has received research support from Janssen and Novartis; consultant fees from Abbott, AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB; and speakers bureau support from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. PSH has received consulting fees from Eli Lilly and fees for educational services from Amgen, Janssen, Novartis, and Pfizer. WHB has received research support from Pfizer and consulting fees and speaker bureau support from AbbVie, Almirall, Celgene, Janssen, LEO Pharma, Eli Lilly, Novartis, and UCB. IBM has received research support from AstraZeneca, BMS, Celgene, Janssen, Eli Lilly, Novartis, and UCB, and consultant fees from AbbVie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Gilead, Janssen, Novartis, and UCB. ABG has received research support from Boehringer Ingelheim, Incyte, Janssen, Novartis, Sun Pharmaceutical Industries, UCB, and XBiotech; honoraria from Amgen, BMS, Celgene, Janssen, LEO Pharma, Novartis, and UCB Pharma; consultant fees from AnaptysBio, Avotres, Boehringer Ingelheim, Incyte, Lilly ICOS, Novartis, Pfizer, and Sun Pharmaceutical Industries; and stock options from XBiotech. PJM has received research support, consulting fees, and speaker bureau support from AbbVie, Amgen, BMS, Celgene, Crescendo Bioscience, Genentech, Janssen, Eli Lilly, Merck, Novartis, Pfizer, and UCB. SK was an employee of Janssen Scientific Affairs at the time this work was performed; APK, ECH, XLX, SS, PA, BZ, PR, and YZ are employees of Janssen Research & Development; and MS is an employee of Janssen Global Services—these authors own stock or stock options in Johnson & Johnson. Address correspondence to Dr. P. Rahman, 154 LeMarchant Road, St. Clare's Mercy Hospital, St. John's, NL A1C 5B8, Canada. Email: prahman@mun.ca. Accepted for publication April 20, 2021.
Christopher T. Ritchlin
This study was sponsored by Janssen Research & Development. P. Rahman, MD, Memorial University of Newfoundland, St. John's, Newfoundland, Canada; C.T. Ritchlin, MD, MPH, University of Rochester, Rochester, New York, USA; P.S. Helliwell, PhD, University of Leeds, Leeds, UK; W.H. Boehncke, MD, Geneva University Hospitals, Geneva, Switzerland; P.J. Mease, MD, Swedish Medical Center/Providence St Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A.B. Gottlieb, MD, PhD, Icahn Medical School at Mount Sinai, New York, New York, USA; S. Kafka, MD, Janssen Scientific Affairs, Horsham, Pennsylvania, USA; A.P. Kollmeier, MD, X.L. Xu, PhD, Janssen Research & Development, San Diego, California, USA; E.C. Hsia, MD, Janssen Research & Development, Spring House, Pennsylvania, USA, and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; M. Shawi, PhD, Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, Pennsylvania, USA; S. Sheng, PhD, P. Agarwal, PhD, B. Zhou, PhD, P. Ramachandran, MD, MPH, Y. Zhuang, PhD, Janssen Research & Development, Spring House, Pennsylvania, USA; I.B. McInnes, MD, PhD, University of Glasgow, Glasgow, UK. CTR has received research support from AbbVie, Amgen, and UCB, and consultant fees from AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB. PR has received research support from Janssen and Novartis; consultant fees from Abbott, AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB; and speakers bureau support from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. PSH has received consulting fees from Eli Lilly and fees for educational services from Amgen, Janssen, Novartis, and Pfizer. WHB has received research support from Pfizer and consulting fees and speaker bureau support from AbbVie, Almirall, Celgene, Janssen, LEO Pharma, Eli Lilly, Novartis, and UCB. IBM has received research support from AstraZeneca, BMS, Celgene, Janssen, Eli Lilly, Novartis, and UCB, and consultant fees from AbbVie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Gilead, Janssen, Novartis, and UCB. ABG has received research support from Boehringer Ingelheim, Incyte, Janssen, Novartis, Sun Pharmaceutical Industries, UCB, and XBiotech; honoraria from Amgen, BMS, Celgene, Janssen, LEO Pharma, Novartis, and UCB Pharma; consultant fees from AnaptysBio, Avotres, Boehringer Ingelheim, Incyte, Lilly ICOS, Novartis, Pfizer, and Sun Pharmaceutical Industries; and stock options from XBiotech. PJM has received research support, consulting fees, and speaker bureau support from AbbVie, Amgen, BMS, Celgene, Crescendo Bioscience, Genentech, Janssen, Eli Lilly, Merck, Novartis, Pfizer, and UCB. SK was an employee of Janssen Scientific Affairs at the time this work was performed; APK, ECH, XLX, SS, PA, BZ, PR, and YZ are employees of Janssen Research & Development; and MS is an employee of Janssen Global Services—these authors own stock or stock options in Johnson & Johnson. Address correspondence to Dr. P. Rahman, 154 LeMarchant Road, St. Clare's Mercy Hospital, St. John's, NL A1C 5B8, Canada. Email: prahman@mun.ca. Accepted for publication April 20, 2021.
Philip S. Helliwell
This study was sponsored by Janssen Research & Development. P. Rahman, MD, Memorial University of Newfoundland, St. John's, Newfoundland, Canada; C.T. Ritchlin, MD, MPH, University of Rochester, Rochester, New York, USA; P.S. Helliwell, PhD, University of Leeds, Leeds, UK; W.H. Boehncke, MD, Geneva University Hospitals, Geneva, Switzerland; P.J. Mease, MD, Swedish Medical Center/Providence St Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A.B. Gottlieb, MD, PhD, Icahn Medical School at Mount Sinai, New York, New York, USA; S. Kafka, MD, Janssen Scientific Affairs, Horsham, Pennsylvania, USA; A.P. Kollmeier, MD, X.L. Xu, PhD, Janssen Research & Development, San Diego, California, USA; E.C. Hsia, MD, Janssen Research & Development, Spring House, Pennsylvania, USA, and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; M. Shawi, PhD, Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, Pennsylvania, USA; S. Sheng, PhD, P. Agarwal, PhD, B. Zhou, PhD, P. Ramachandran, MD, MPH, Y. Zhuang, PhD, Janssen Research & Development, Spring House, Pennsylvania, USA; I.B. McInnes, MD, PhD, University of Glasgow, Glasgow, UK. CTR has received research support from AbbVie, Amgen, and UCB, and consultant fees from AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB. PR has received research support from Janssen and Novartis; consultant fees from Abbott, AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB; and speakers bureau support from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. PSH has received consulting fees from Eli Lilly and fees for educational services from Amgen, Janssen, Novartis, and Pfizer. WHB has received research support from Pfizer and consulting fees and speaker bureau support from AbbVie, Almirall, Celgene, Janssen, LEO Pharma, Eli Lilly, Novartis, and UCB. IBM has received research support from AstraZeneca, BMS, Celgene, Janssen, Eli Lilly, Novartis, and UCB, and consultant fees from AbbVie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Gilead, Janssen, Novartis, and UCB. ABG has received research support from Boehringer Ingelheim, Incyte, Janssen, Novartis, Sun Pharmaceutical Industries, UCB, and XBiotech; honoraria from Amgen, BMS, Celgene, Janssen, LEO Pharma, Novartis, and UCB Pharma; consultant fees from AnaptysBio, Avotres, Boehringer Ingelheim, Incyte, Lilly ICOS, Novartis, Pfizer, and Sun Pharmaceutical Industries; and stock options from XBiotech. PJM has received research support, consulting fees, and speaker bureau support from AbbVie, Amgen, BMS, Celgene, Crescendo Bioscience, Genentech, Janssen, Eli Lilly, Merck, Novartis, Pfizer, and UCB. SK was an employee of Janssen Scientific Affairs at the time this work was performed; APK, ECH, XLX, SS, PA, BZ, PR, and YZ are employees of Janssen Research & Development; and MS is an employee of Janssen Global Services—these authors own stock or stock options in Johnson & Johnson. Address correspondence to Dr. P. Rahman, 154 LeMarchant Road, St. Clare's Mercy Hospital, St. John's, NL A1C 5B8, Canada. Email: prahman@mun.ca. Accepted for publication April 20, 2021.
Wolf-Henning Boehncke
This study was sponsored by Janssen Research & Development. P. Rahman, MD, Memorial University of Newfoundland, St. John's, Newfoundland, Canada; C.T. Ritchlin, MD, MPH, University of Rochester, Rochester, New York, USA; P.S. Helliwell, PhD, University of Leeds, Leeds, UK; W.H. Boehncke, MD, Geneva University Hospitals, Geneva, Switzerland; P.J. Mease, MD, Swedish Medical Center/Providence St Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A.B. Gottlieb, MD, PhD, Icahn Medical School at Mount Sinai, New York, New York, USA; S. Kafka, MD, Janssen Scientific Affairs, Horsham, Pennsylvania, USA; A.P. Kollmeier, MD, X.L. Xu, PhD, Janssen Research & Development, San Diego, California, USA; E.C. Hsia, MD, Janssen Research & Development, Spring House, Pennsylvania, USA, and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; M. Shawi, PhD, Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, Pennsylvania, USA; S. Sheng, PhD, P. Agarwal, PhD, B. Zhou, PhD, P. Ramachandran, MD, MPH, Y. Zhuang, PhD, Janssen Research & Development, Spring House, Pennsylvania, USA; I.B. McInnes, MD, PhD, University of Glasgow, Glasgow, UK. CTR has received research support from AbbVie, Amgen, and UCB, and consultant fees from AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB. PR has received research support from Janssen and Novartis; consultant fees from Abbott, AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB; and speakers bureau support from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. PSH has received consulting fees from Eli Lilly and fees for educational services from Amgen, Janssen, Novartis, and Pfizer. WHB has received research support from Pfizer and consulting fees and speaker bureau support from AbbVie, Almirall, Celgene, Janssen, LEO Pharma, Eli Lilly, Novartis, and UCB. IBM has received research support from AstraZeneca, BMS, Celgene, Janssen, Eli Lilly, Novartis, and UCB, and consultant fees from AbbVie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Gilead, Janssen, Novartis, and UCB. ABG has received research support from Boehringer Ingelheim, Incyte, Janssen, Novartis, Sun Pharmaceutical Industries, UCB, and XBiotech; honoraria from Amgen, BMS, Celgene, Janssen, LEO Pharma, Novartis, and UCB Pharma; consultant fees from AnaptysBio, Avotres, Boehringer Ingelheim, Incyte, Lilly ICOS, Novartis, Pfizer, and Sun Pharmaceutical Industries; and stock options from XBiotech. PJM has received research support, consulting fees, and speaker bureau support from AbbVie, Amgen, BMS, Celgene, Crescendo Bioscience, Genentech, Janssen, Eli Lilly, Merck, Novartis, Pfizer, and UCB. SK was an employee of Janssen Scientific Affairs at the time this work was performed; APK, ECH, XLX, SS, PA, BZ, PR, and YZ are employees of Janssen Research & Development; and MS is an employee of Janssen Global Services—these authors own stock or stock options in Johnson & Johnson. Address correspondence to Dr. P. Rahman, 154 LeMarchant Road, St. Clare's Mercy Hospital, St. John's, NL A1C 5B8, Canada. Email: prahman@mun.ca. Accepted for publication April 20, 2021.
Philip J. Mease
This study was sponsored by Janssen Research & Development. P. Rahman, MD, Memorial University of Newfoundland, St. John's, Newfoundland, Canada; C.T. Ritchlin, MD, MPH, University of Rochester, Rochester, New York, USA; P.S. Helliwell, PhD, University of Leeds, Leeds, UK; W.H. Boehncke, MD, Geneva University Hospitals, Geneva, Switzerland; P.J. Mease, MD, Swedish Medical Center/Providence St Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A.B. Gottlieb, MD, PhD, Icahn Medical School at Mount Sinai, New York, New York, USA; S. Kafka, MD, Janssen Scientific Affairs, Horsham, Pennsylvania, USA; A.P. Kollmeier, MD, X.L. Xu, PhD, Janssen Research & Development, San Diego, California, USA; E.C. Hsia, MD, Janssen Research & Development, Spring House, Pennsylvania, USA, and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; M. Shawi, PhD, Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, Pennsylvania, USA; S. Sheng, PhD, P. Agarwal, PhD, B. Zhou, PhD, P. Ramachandran, MD, MPH, Y. Zhuang, PhD, Janssen Research & Development, Spring House, Pennsylvania, USA; I.B. McInnes, MD, PhD, University of Glasgow, Glasgow, UK. CTR has received research support from AbbVie, Amgen, and UCB, and consultant fees from AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB. PR has received research support from Janssen and Novartis; consultant fees from Abbott, AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB; and speakers bureau support from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. PSH has received consulting fees from Eli Lilly and fees for educational services from Amgen, Janssen, Novartis, and Pfizer. WHB has received research support from Pfizer and consulting fees and speaker bureau support from AbbVie, Almirall, Celgene, Janssen, LEO Pharma, Eli Lilly, Novartis, and UCB. IBM has received research support from AstraZeneca, BMS, Celgene, Janssen, Eli Lilly, Novartis, and UCB, and consultant fees from AbbVie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Gilead, Janssen, Novartis, and UCB. ABG has received research support from Boehringer Ingelheim, Incyte, Janssen, Novartis, Sun Pharmaceutical Industries, UCB, and XBiotech; honoraria from Amgen, BMS, Celgene, Janssen, LEO Pharma, Novartis, and UCB Pharma; consultant fees from AnaptysBio, Avotres, Boehringer Ingelheim, Incyte, Lilly ICOS, Novartis, Pfizer, and Sun Pharmaceutical Industries; and stock options from XBiotech. PJM has received research support, consulting fees, and speaker bureau support from AbbVie, Amgen, BMS, Celgene, Crescendo Bioscience, Genentech, Janssen, Eli Lilly, Merck, Novartis, Pfizer, and UCB. SK was an employee of Janssen Scientific Affairs at the time this work was performed; APK, ECH, XLX, SS, PA, BZ, PR, and YZ are employees of Janssen Research & Development; and MS is an employee of Janssen Global Services—these authors own stock or stock options in Johnson & Johnson. Address correspondence to Dr. P. Rahman, 154 LeMarchant Road, St. Clare's Mercy Hospital, St. John's, NL A1C 5B8, Canada. Email: prahman@mun.ca. Accepted for publication April 20, 2021.
Alice B. Gottlieb
This study was sponsored by Janssen Research & Development. P. Rahman, MD, Memorial University of Newfoundland, St. John's, Newfoundland, Canada; C.T. Ritchlin, MD, MPH, University of Rochester, Rochester, New York, USA; P.S. Helliwell, PhD, University of Leeds, Leeds, UK; W.H. Boehncke, MD, Geneva University Hospitals, Geneva, Switzerland; P.J. Mease, MD, Swedish Medical Center/Providence St Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A.B. Gottlieb, MD, PhD, Icahn Medical School at Mount Sinai, New York, New York, USA; S. Kafka, MD, Janssen Scientific Affairs, Horsham, Pennsylvania, USA; A.P. Kollmeier, MD, X.L. Xu, PhD, Janssen Research & Development, San Diego, California, USA; E.C. Hsia, MD, Janssen Research & Development, Spring House, Pennsylvania, USA, and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; M. Shawi, PhD, Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, Pennsylvania, USA; S. Sheng, PhD, P. Agarwal, PhD, B. Zhou, PhD, P. Ramachandran, MD, MPH, Y. Zhuang, PhD, Janssen Research & Development, Spring House, Pennsylvania, USA; I.B. McInnes, MD, PhD, University of Glasgow, Glasgow, UK. CTR has received research support from AbbVie, Amgen, and UCB, and consultant fees from AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB. PR has received research support from Janssen and Novartis; consultant fees from Abbott, AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB; and speakers bureau support from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. PSH has received consulting fees from Eli Lilly and fees for educational services from Amgen, Janssen, Novartis, and Pfizer. WHB has received research support from Pfizer and consulting fees and speaker bureau support from AbbVie, Almirall, Celgene, Janssen, LEO Pharma, Eli Lilly, Novartis, and UCB. IBM has received research support from AstraZeneca, BMS, Celgene, Janssen, Eli Lilly, Novartis, and UCB, and consultant fees from AbbVie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Gilead, Janssen, Novartis, and UCB. ABG has received research support from Boehringer Ingelheim, Incyte, Janssen, Novartis, Sun Pharmaceutical Industries, UCB, and XBiotech; honoraria from Amgen, BMS, Celgene, Janssen, LEO Pharma, Novartis, and UCB Pharma; consultant fees from AnaptysBio, Avotres, Boehringer Ingelheim, Incyte, Lilly ICOS, Novartis, Pfizer, and Sun Pharmaceutical Industries; and stock options from XBiotech. PJM has received research support, consulting fees, and speaker bureau support from AbbVie, Amgen, BMS, Celgene, Crescendo Bioscience, Genentech, Janssen, Eli Lilly, Merck, Novartis, Pfizer, and UCB. SK was an employee of Janssen Scientific Affairs at the time this work was performed; APK, ECH, XLX, SS, PA, BZ, PR, and YZ are employees of Janssen Research & Development; and MS is an employee of Janssen Global Services—these authors own stock or stock options in Johnson & Johnson. Address correspondence to Dr. P. Rahman, 154 LeMarchant Road, St. Clare's Mercy Hospital, St. John's, NL A1C 5B8, Canada. Email: prahman@mun.ca. Accepted for publication April 20, 2021.
Shelly Kafka
This study was sponsored by Janssen Research & Development. P. Rahman, MD, Memorial University of Newfoundland, St. John's, Newfoundland, Canada; C.T. Ritchlin, MD, MPH, University of Rochester, Rochester, New York, USA; P.S. Helliwell, PhD, University of Leeds, Leeds, UK; W.H. Boehncke, MD, Geneva University Hospitals, Geneva, Switzerland; P.J. Mease, MD, Swedish Medical Center/Providence St Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A.B. Gottlieb, MD, PhD, Icahn Medical School at Mount Sinai, New York, New York, USA; S. Kafka, MD, Janssen Scientific Affairs, Horsham, Pennsylvania, USA; A.P. Kollmeier, MD, X.L. Xu, PhD, Janssen Research & Development, San Diego, California, USA; E.C. Hsia, MD, Janssen Research & Development, Spring House, Pennsylvania, USA, and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; M. Shawi, PhD, Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, Pennsylvania, USA; S. Sheng, PhD, P. Agarwal, PhD, B. Zhou, PhD, P. Ramachandran, MD, MPH, Y. Zhuang, PhD, Janssen Research & Development, Spring House, Pennsylvania, USA; I.B. McInnes, MD, PhD, University of Glasgow, Glasgow, UK. CTR has received research support from AbbVie, Amgen, and UCB, and consultant fees from AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB. PR has received research support from Janssen and Novartis; consultant fees from Abbott, AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB; and speakers bureau support from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. PSH has received consulting fees from Eli Lilly and fees for educational services from Amgen, Janssen, Novartis, and Pfizer. WHB has received research support from Pfizer and consulting fees and speaker bureau support from AbbVie, Almirall, Celgene, Janssen, LEO Pharma, Eli Lilly, Novartis, and UCB. IBM has received research support from AstraZeneca, BMS, Celgene, Janssen, Eli Lilly, Novartis, and UCB, and consultant fees from AbbVie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Gilead, Janssen, Novartis, and UCB. ABG has received research support from Boehringer Ingelheim, Incyte, Janssen, Novartis, Sun Pharmaceutical Industries, UCB, and XBiotech; honoraria from Amgen, BMS, Celgene, Janssen, LEO Pharma, Novartis, and UCB Pharma; consultant fees from AnaptysBio, Avotres, Boehringer Ingelheim, Incyte, Lilly ICOS, Novartis, Pfizer, and Sun Pharmaceutical Industries; and stock options from XBiotech. PJM has received research support, consulting fees, and speaker bureau support from AbbVie, Amgen, BMS, Celgene, Crescendo Bioscience, Genentech, Janssen, Eli Lilly, Merck, Novartis, Pfizer, and UCB. SK was an employee of Janssen Scientific Affairs at the time this work was performed; APK, ECH, XLX, SS, PA, BZ, PR, and YZ are employees of Janssen Research & Development; and MS is an employee of Janssen Global Services—these authors own stock or stock options in Johnson & Johnson. Address correspondence to Dr. P. Rahman, 154 LeMarchant Road, St. Clare's Mercy Hospital, St. John's, NL A1C 5B8, Canada. Email: prahman@mun.ca. Accepted for publication April 20, 2021.
Alexa P. Kollmeier
This study was sponsored by Janssen Research & Development. P. Rahman, MD, Memorial University of Newfoundland, St. John's, Newfoundland, Canada; C.T. Ritchlin, MD, MPH, University of Rochester, Rochester, New York, USA; P.S. Helliwell, PhD, University of Leeds, Leeds, UK; W.H. Boehncke, MD, Geneva University Hospitals, Geneva, Switzerland; P.J. Mease, MD, Swedish Medical Center/Providence St Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A.B. Gottlieb, MD, PhD, Icahn Medical School at Mount Sinai, New York, New York, USA; S. Kafka, MD, Janssen Scientific Affairs, Horsham, Pennsylvania, USA; A.P. Kollmeier, MD, X.L. Xu, PhD, Janssen Research & Development, San Diego, California, USA; E.C. Hsia, MD, Janssen Research & Development, Spring House, Pennsylvania, USA, and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; M. Shawi, PhD, Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, Pennsylvania, USA; S. Sheng, PhD, P. Agarwal, PhD, B. Zhou, PhD, P. Ramachandran, MD, MPH, Y. Zhuang, PhD, Janssen Research & Development, Spring House, Pennsylvania, USA; I.B. McInnes, MD, PhD, University of Glasgow, Glasgow, UK. CTR has received research support from AbbVie, Amgen, and UCB, and consultant fees from AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB. PR has received research support from Janssen and Novartis; consultant fees from Abbott, AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB; and speakers bureau support from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. PSH has received consulting fees from Eli Lilly and fees for educational services from Amgen, Janssen, Novartis, and Pfizer. WHB has received research support from Pfizer and consulting fees and speaker bureau support from AbbVie, Almirall, Celgene, Janssen, LEO Pharma, Eli Lilly, Novartis, and UCB. IBM has received research support from AstraZeneca, BMS, Celgene, Janssen, Eli Lilly, Novartis, and UCB, and consultant fees from AbbVie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Gilead, Janssen, Novartis, and UCB. ABG has received research support from Boehringer Ingelheim, Incyte, Janssen, Novartis, Sun Pharmaceutical Industries, UCB, and XBiotech; honoraria from Amgen, BMS, Celgene, Janssen, LEO Pharma, Novartis, and UCB Pharma; consultant fees from AnaptysBio, Avotres, Boehringer Ingelheim, Incyte, Lilly ICOS, Novartis, Pfizer, and Sun Pharmaceutical Industries; and stock options from XBiotech. PJM has received research support, consulting fees, and speaker bureau support from AbbVie, Amgen, BMS, Celgene, Crescendo Bioscience, Genentech, Janssen, Eli Lilly, Merck, Novartis, Pfizer, and UCB. SK was an employee of Janssen Scientific Affairs at the time this work was performed; APK, ECH, XLX, SS, PA, BZ, PR, and YZ are employees of Janssen Research & Development; and MS is an employee of Janssen Global Services—these authors own stock or stock options in Johnson & Johnson. Address correspondence to Dr. P. Rahman, 154 LeMarchant Road, St. Clare's Mercy Hospital, St. John's, NL A1C 5B8, Canada. Email: prahman@mun.ca. Accepted for publication April 20, 2021.
Elizabeth C. Hsia
This study was sponsored by Janssen Research & Development. P. Rahman, MD, Memorial University of Newfoundland, St. John's, Newfoundland, Canada; C.T. Ritchlin, MD, MPH, University of Rochester, Rochester, New York, USA; P.S. Helliwell, PhD, University of Leeds, Leeds, UK; W.H. Boehncke, MD, Geneva University Hospitals, Geneva, Switzerland; P.J. Mease, MD, Swedish Medical Center/Providence St Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A.B. Gottlieb, MD, PhD, Icahn Medical School at Mount Sinai, New York, New York, USA; S. Kafka, MD, Janssen Scientific Affairs, Horsham, Pennsylvania, USA; A.P. Kollmeier, MD, X.L. Xu, PhD, Janssen Research & Development, San Diego, California, USA; E.C. Hsia, MD, Janssen Research & Development, Spring House, Pennsylvania, USA, and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; M. Shawi, PhD, Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, Pennsylvania, USA; S. Sheng, PhD, P. Agarwal, PhD, B. Zhou, PhD, P. Ramachandran, MD, MPH, Y. Zhuang, PhD, Janssen Research & Development, Spring House, Pennsylvania, USA; I.B. McInnes, MD, PhD, University of Glasgow, Glasgow, UK. CTR has received research support from AbbVie, Amgen, and UCB, and consultant fees from AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB. PR has received research support from Janssen and Novartis; consultant fees from Abbott, AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB; and speakers bureau support from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. PSH has received consulting fees from Eli Lilly and fees for educational services from Amgen, Janssen, Novartis, and Pfizer. WHB has received research support from Pfizer and consulting fees and speaker bureau support from AbbVie, Almirall, Celgene, Janssen, LEO Pharma, Eli Lilly, Novartis, and UCB. IBM has received research support from AstraZeneca, BMS, Celgene, Janssen, Eli Lilly, Novartis, and UCB, and consultant fees from AbbVie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Gilead, Janssen, Novartis, and UCB. ABG has received research support from Boehringer Ingelheim, Incyte, Janssen, Novartis, Sun Pharmaceutical Industries, UCB, and XBiotech; honoraria from Amgen, BMS, Celgene, Janssen, LEO Pharma, Novartis, and UCB Pharma; consultant fees from AnaptysBio, Avotres, Boehringer Ingelheim, Incyte, Lilly ICOS, Novartis, Pfizer, and Sun Pharmaceutical Industries; and stock options from XBiotech. PJM has received research support, consulting fees, and speaker bureau support from AbbVie, Amgen, BMS, Celgene, Crescendo Bioscience, Genentech, Janssen, Eli Lilly, Merck, Novartis, Pfizer, and UCB. SK was an employee of Janssen Scientific Affairs at the time this work was performed; APK, ECH, XLX, SS, PA, BZ, PR, and YZ are employees of Janssen Research & Development; and MS is an employee of Janssen Global Services—these authors own stock or stock options in Johnson & Johnson. Address correspondence to Dr. P. Rahman, 154 LeMarchant Road, St. Clare's Mercy Hospital, St. John's, NL A1C 5B8, Canada. Email: prahman@mun.ca. Accepted for publication April 20, 2021.
Xie L. Xu
This study was sponsored by Janssen Research & Development. P. Rahman, MD, Memorial University of Newfoundland, St. John's, Newfoundland, Canada; C.T. Ritchlin, MD, MPH, University of Rochester, Rochester, New York, USA; P.S. Helliwell, PhD, University of Leeds, Leeds, UK; W.H. Boehncke, MD, Geneva University Hospitals, Geneva, Switzerland; P.J. Mease, MD, Swedish Medical Center/Providence St Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A.B. Gottlieb, MD, PhD, Icahn Medical School at Mount Sinai, New York, New York, USA; S. Kafka, MD, Janssen Scientific Affairs, Horsham, Pennsylvania, USA; A.P. Kollmeier, MD, X.L. Xu, PhD, Janssen Research & Development, San Diego, California, USA; E.C. Hsia, MD, Janssen Research & Development, Spring House, Pennsylvania, USA, and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; M. Shawi, PhD, Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, Pennsylvania, USA; S. Sheng, PhD, P. Agarwal, PhD, B. Zhou, PhD, P. Ramachandran, MD, MPH, Y. Zhuang, PhD, Janssen Research & Development, Spring House, Pennsylvania, USA; I.B. McInnes, MD, PhD, University of Glasgow, Glasgow, UK. CTR has received research support from AbbVie, Amgen, and UCB, and consultant fees from AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB. PR has received research support from Janssen and Novartis; consultant fees from Abbott, AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB; and speakers bureau support from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. PSH has received consulting fees from Eli Lilly and fees for educational services from Amgen, Janssen, Novartis, and Pfizer. WHB has received research support from Pfizer and consulting fees and speaker bureau support from AbbVie, Almirall, Celgene, Janssen, LEO Pharma, Eli Lilly, Novartis, and UCB. IBM has received research support from AstraZeneca, BMS, Celgene, Janssen, Eli Lilly, Novartis, and UCB, and consultant fees from AbbVie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Gilead, Janssen, Novartis, and UCB. ABG has received research support from Boehringer Ingelheim, Incyte, Janssen, Novartis, Sun Pharmaceutical Industries, UCB, and XBiotech; honoraria from Amgen, BMS, Celgene, Janssen, LEO Pharma, Novartis, and UCB Pharma; consultant fees from AnaptysBio, Avotres, Boehringer Ingelheim, Incyte, Lilly ICOS, Novartis, Pfizer, and Sun Pharmaceutical Industries; and stock options from XBiotech. PJM has received research support, consulting fees, and speaker bureau support from AbbVie, Amgen, BMS, Celgene, Crescendo Bioscience, Genentech, Janssen, Eli Lilly, Merck, Novartis, Pfizer, and UCB. SK was an employee of Janssen Scientific Affairs at the time this work was performed; APK, ECH, XLX, SS, PA, BZ, PR, and YZ are employees of Janssen Research & Development; and MS is an employee of Janssen Global Services—these authors own stock or stock options in Johnson & Johnson. Address correspondence to Dr. P. Rahman, 154 LeMarchant Road, St. Clare's Mercy Hospital, St. John's, NL A1C 5B8, Canada. Email: prahman@mun.ca. Accepted for publication April 20, 2021.
May Shawi
This study was sponsored by Janssen Research & Development. P. Rahman, MD, Memorial University of Newfoundland, St. John's, Newfoundland, Canada; C.T. Ritchlin, MD, MPH, University of Rochester, Rochester, New York, USA; P.S. Helliwell, PhD, University of Leeds, Leeds, UK; W.H. Boehncke, MD, Geneva University Hospitals, Geneva, Switzerland; P.J. Mease, MD, Swedish Medical Center/Providence St Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A.B. Gottlieb, MD, PhD, Icahn Medical School at Mount Sinai, New York, New York, USA; S. Kafka, MD, Janssen Scientific Affairs, Horsham, Pennsylvania, USA; A.P. Kollmeier, MD, X.L. Xu, PhD, Janssen Research & Development, San Diego, California, USA; E.C. Hsia, MD, Janssen Research & Development, Spring House, Pennsylvania, USA, and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; M. Shawi, PhD, Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, Pennsylvania, USA; S. Sheng, PhD, P. Agarwal, PhD, B. Zhou, PhD, P. Ramachandran, MD, MPH, Y. Zhuang, PhD, Janssen Research & Development, Spring House, Pennsylvania, USA; I.B. McInnes, MD, PhD, University of Glasgow, Glasgow, UK. CTR has received research support from AbbVie, Amgen, and UCB, and consultant fees from AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB. PR has received research support from Janssen and Novartis; consultant fees from Abbott, AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB; and speakers bureau support from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. PSH has received consulting fees from Eli Lilly and fees for educational services from Amgen, Janssen, Novartis, and Pfizer. WHB has received research support from Pfizer and consulting fees and speaker bureau support from AbbVie, Almirall, Celgene, Janssen, LEO Pharma, Eli Lilly, Novartis, and UCB. IBM has received research support from AstraZeneca, BMS, Celgene, Janssen, Eli Lilly, Novartis, and UCB, and consultant fees from AbbVie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Gilead, Janssen, Novartis, and UCB. ABG has received research support from Boehringer Ingelheim, Incyte, Janssen, Novartis, Sun Pharmaceutical Industries, UCB, and XBiotech; honoraria from Amgen, BMS, Celgene, Janssen, LEO Pharma, Novartis, and UCB Pharma; consultant fees from AnaptysBio, Avotres, Boehringer Ingelheim, Incyte, Lilly ICOS, Novartis, Pfizer, and Sun Pharmaceutical Industries; and stock options from XBiotech. PJM has received research support, consulting fees, and speaker bureau support from AbbVie, Amgen, BMS, Celgene, Crescendo Bioscience, Genentech, Janssen, Eli Lilly, Merck, Novartis, Pfizer, and UCB. SK was an employee of Janssen Scientific Affairs at the time this work was performed; APK, ECH, XLX, SS, PA, BZ, PR, and YZ are employees of Janssen Research & Development; and MS is an employee of Janssen Global Services—these authors own stock or stock options in Johnson & Johnson. Address correspondence to Dr. P. Rahman, 154 LeMarchant Road, St. Clare's Mercy Hospital, St. John's, NL A1C 5B8, Canada. Email: prahman@mun.ca. Accepted for publication April 20, 2021.
Shihong Sheng
This study was sponsored by Janssen Research & Development. P. Rahman, MD, Memorial University of Newfoundland, St. John's, Newfoundland, Canada; C.T. Ritchlin, MD, MPH, University of Rochester, Rochester, New York, USA; P.S. Helliwell, PhD, University of Leeds, Leeds, UK; W.H. Boehncke, MD, Geneva University Hospitals, Geneva, Switzerland; P.J. Mease, MD, Swedish Medical Center/Providence St Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A.B. Gottlieb, MD, PhD, Icahn Medical School at Mount Sinai, New York, New York, USA; S. Kafka, MD, Janssen Scientific Affairs, Horsham, Pennsylvania, USA; A.P. Kollmeier, MD, X.L. Xu, PhD, Janssen Research & Development, San Diego, California, USA; E.C. Hsia, MD, Janssen Research & Development, Spring House, Pennsylvania, USA, and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; M. Shawi, PhD, Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, Pennsylvania, USA; S. Sheng, PhD, P. Agarwal, PhD, B. Zhou, PhD, P. Ramachandran, MD, MPH, Y. Zhuang, PhD, Janssen Research & Development, Spring House, Pennsylvania, USA; I.B. McInnes, MD, PhD, University of Glasgow, Glasgow, UK. CTR has received research support from AbbVie, Amgen, and UCB, and consultant fees from AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB. PR has received research support from Janssen and Novartis; consultant fees from Abbott, AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB; and speakers bureau support from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. PSH has received consulting fees from Eli Lilly and fees for educational services from Amgen, Janssen, Novartis, and Pfizer. WHB has received research support from Pfizer and consulting fees and speaker bureau support from AbbVie, Almirall, Celgene, Janssen, LEO Pharma, Eli Lilly, Novartis, and UCB. IBM has received research support from AstraZeneca, BMS, Celgene, Janssen, Eli Lilly, Novartis, and UCB, and consultant fees from AbbVie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Gilead, Janssen, Novartis, and UCB. ABG has received research support from Boehringer Ingelheim, Incyte, Janssen, Novartis, Sun Pharmaceutical Industries, UCB, and XBiotech; honoraria from Amgen, BMS, Celgene, Janssen, LEO Pharma, Novartis, and UCB Pharma; consultant fees from AnaptysBio, Avotres, Boehringer Ingelheim, Incyte, Lilly ICOS, Novartis, Pfizer, and Sun Pharmaceutical Industries; and stock options from XBiotech. PJM has received research support, consulting fees, and speaker bureau support from AbbVie, Amgen, BMS, Celgene, Crescendo Bioscience, Genentech, Janssen, Eli Lilly, Merck, Novartis, Pfizer, and UCB. SK was an employee of Janssen Scientific Affairs at the time this work was performed; APK, ECH, XLX, SS, PA, BZ, PR, and YZ are employees of Janssen Research & Development; and MS is an employee of Janssen Global Services—these authors own stock or stock options in Johnson & Johnson. Address correspondence to Dr. P. Rahman, 154 LeMarchant Road, St. Clare's Mercy Hospital, St. John's, NL A1C 5B8, Canada. Email: prahman@mun.ca. Accepted for publication April 20, 2021.
Prasheen Agarwal
This study was sponsored by Janssen Research & Development. P. Rahman, MD, Memorial University of Newfoundland, St. John's, Newfoundland, Canada; C.T. Ritchlin, MD, MPH, University of Rochester, Rochester, New York, USA; P.S. Helliwell, PhD, University of Leeds, Leeds, UK; W.H. Boehncke, MD, Geneva University Hospitals, Geneva, Switzerland; P.J. Mease, MD, Swedish Medical Center/Providence St Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A.B. Gottlieb, MD, PhD, Icahn Medical School at Mount Sinai, New York, New York, USA; S. Kafka, MD, Janssen Scientific Affairs, Horsham, Pennsylvania, USA; A.P. Kollmeier, MD, X.L. Xu, PhD, Janssen Research & Development, San Diego, California, USA; E.C. Hsia, MD, Janssen Research & Development, Spring House, Pennsylvania, USA, and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; M. Shawi, PhD, Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, Pennsylvania, USA; S. Sheng, PhD, P. Agarwal, PhD, B. Zhou, PhD, P. Ramachandran, MD, MPH, Y. Zhuang, PhD, Janssen Research & Development, Spring House, Pennsylvania, USA; I.B. McInnes, MD, PhD, University of Glasgow, Glasgow, UK. CTR has received research support from AbbVie, Amgen, and UCB, and consultant fees from AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB. PR has received research support from Janssen and Novartis; consultant fees from Abbott, AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB; and speakers bureau support from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. PSH has received consulting fees from Eli Lilly and fees for educational services from Amgen, Janssen, Novartis, and Pfizer. WHB has received research support from Pfizer and consulting fees and speaker bureau support from AbbVie, Almirall, Celgene, Janssen, LEO Pharma, Eli Lilly, Novartis, and UCB. IBM has received research support from AstraZeneca, BMS, Celgene, Janssen, Eli Lilly, Novartis, and UCB, and consultant fees from AbbVie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Gilead, Janssen, Novartis, and UCB. ABG has received research support from Boehringer Ingelheim, Incyte, Janssen, Novartis, Sun Pharmaceutical Industries, UCB, and XBiotech; honoraria from Amgen, BMS, Celgene, Janssen, LEO Pharma, Novartis, and UCB Pharma; consultant fees from AnaptysBio, Avotres, Boehringer Ingelheim, Incyte, Lilly ICOS, Novartis, Pfizer, and Sun Pharmaceutical Industries; and stock options from XBiotech. PJM has received research support, consulting fees, and speaker bureau support from AbbVie, Amgen, BMS, Celgene, Crescendo Bioscience, Genentech, Janssen, Eli Lilly, Merck, Novartis, Pfizer, and UCB. SK was an employee of Janssen Scientific Affairs at the time this work was performed; APK, ECH, XLX, SS, PA, BZ, PR, and YZ are employees of Janssen Research & Development; and MS is an employee of Janssen Global Services—these authors own stock or stock options in Johnson & Johnson. Address correspondence to Dr. P. Rahman, 154 LeMarchant Road, St. Clare's Mercy Hospital, St. John's, NL A1C 5B8, Canada. Email: prahman@mun.ca. Accepted for publication April 20, 2021.
Bei Zhou
This study was sponsored by Janssen Research & Development. P. Rahman, MD, Memorial University of Newfoundland, St. John's, Newfoundland, Canada; C.T. Ritchlin, MD, MPH, University of Rochester, Rochester, New York, USA; P.S. Helliwell, PhD, University of Leeds, Leeds, UK; W.H. Boehncke, MD, Geneva University Hospitals, Geneva, Switzerland; P.J. Mease, MD, Swedish Medical Center/Providence St Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A.B. Gottlieb, MD, PhD, Icahn Medical School at Mount Sinai, New York, New York, USA; S. Kafka, MD, Janssen Scientific Affairs, Horsham, Pennsylvania, USA; A.P. Kollmeier, MD, X.L. Xu, PhD, Janssen Research & Development, San Diego, California, USA; E.C. Hsia, MD, Janssen Research & Development, Spring House, Pennsylvania, USA, and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; M. Shawi, PhD, Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, Pennsylvania, USA; S. Sheng, PhD, P. Agarwal, PhD, B. Zhou, PhD, P. Ramachandran, MD, MPH, Y. Zhuang, PhD, Janssen Research & Development, Spring House, Pennsylvania, USA; I.B. McInnes, MD, PhD, University of Glasgow, Glasgow, UK. CTR has received research support from AbbVie, Amgen, and UCB, and consultant fees from AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB. PR has received research support from Janssen and Novartis; consultant fees from Abbott, AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB; and speakers bureau support from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. PSH has received consulting fees from Eli Lilly and fees for educational services from Amgen, Janssen, Novartis, and Pfizer. WHB has received research support from Pfizer and consulting fees and speaker bureau support from AbbVie, Almirall, Celgene, Janssen, LEO Pharma, Eli Lilly, Novartis, and UCB. IBM has received research support from AstraZeneca, BMS, Celgene, Janssen, Eli Lilly, Novartis, and UCB, and consultant fees from AbbVie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Gilead, Janssen, Novartis, and UCB. ABG has received research support from Boehringer Ingelheim, Incyte, Janssen, Novartis, Sun Pharmaceutical Industries, UCB, and XBiotech; honoraria from Amgen, BMS, Celgene, Janssen, LEO Pharma, Novartis, and UCB Pharma; consultant fees from AnaptysBio, Avotres, Boehringer Ingelheim, Incyte, Lilly ICOS, Novartis, Pfizer, and Sun Pharmaceutical Industries; and stock options from XBiotech. PJM has received research support, consulting fees, and speaker bureau support from AbbVie, Amgen, BMS, Celgene, Crescendo Bioscience, Genentech, Janssen, Eli Lilly, Merck, Novartis, Pfizer, and UCB. SK was an employee of Janssen Scientific Affairs at the time this work was performed; APK, ECH, XLX, SS, PA, BZ, PR, and YZ are employees of Janssen Research & Development; and MS is an employee of Janssen Global Services—these authors own stock or stock options in Johnson & Johnson. Address correspondence to Dr. P. Rahman, 154 LeMarchant Road, St. Clare's Mercy Hospital, St. John's, NL A1C 5B8, Canada. Email: prahman@mun.ca. Accepted for publication April 20, 2021.
Paraneedharan Ramachandran
This study was sponsored by Janssen Research & Development. P. Rahman, MD, Memorial University of Newfoundland, St. John's, Newfoundland, Canada; C.T. Ritchlin, MD, MPH, University of Rochester, Rochester, New York, USA; P.S. Helliwell, PhD, University of Leeds, Leeds, UK; W.H. Boehncke, MD, Geneva University Hospitals, Geneva, Switzerland; P.J. Mease, MD, Swedish Medical Center/Providence St Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A.B. Gottlieb, MD, PhD, Icahn Medical School at Mount Sinai, New York, New York, USA; S. Kafka, MD, Janssen Scientific Affairs, Horsham, Pennsylvania, USA; A.P. Kollmeier, MD, X.L. Xu, PhD, Janssen Research & Development, San Diego, California, USA; E.C. Hsia, MD, Janssen Research & Development, Spring House, Pennsylvania, USA, and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; M. Shawi, PhD, Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, Pennsylvania, USA; S. Sheng, PhD, P. Agarwal, PhD, B. Zhou, PhD, P. Ramachandran, MD, MPH, Y. Zhuang, PhD, Janssen Research & Development, Spring House, Pennsylvania, USA; I.B. McInnes, MD, PhD, University of Glasgow, Glasgow, UK. CTR has received research support from AbbVie, Amgen, and UCB, and consultant fees from AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB. PR has received research support from Janssen and Novartis; consultant fees from Abbott, AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB; and speakers bureau support from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. PSH has received consulting fees from Eli Lilly and fees for educational services from Amgen, Janssen, Novartis, and Pfizer. WHB has received research support from Pfizer and consulting fees and speaker bureau support from AbbVie, Almirall, Celgene, Janssen, LEO Pharma, Eli Lilly, Novartis, and UCB. IBM has received research support from AstraZeneca, BMS, Celgene, Janssen, Eli Lilly, Novartis, and UCB, and consultant fees from AbbVie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Gilead, Janssen, Novartis, and UCB. ABG has received research support from Boehringer Ingelheim, Incyte, Janssen, Novartis, Sun Pharmaceutical Industries, UCB, and XBiotech; honoraria from Amgen, BMS, Celgene, Janssen, LEO Pharma, Novartis, and UCB Pharma; consultant fees from AnaptysBio, Avotres, Boehringer Ingelheim, Incyte, Lilly ICOS, Novartis, Pfizer, and Sun Pharmaceutical Industries; and stock options from XBiotech. PJM has received research support, consulting fees, and speaker bureau support from AbbVie, Amgen, BMS, Celgene, Crescendo Bioscience, Genentech, Janssen, Eli Lilly, Merck, Novartis, Pfizer, and UCB. SK was an employee of Janssen Scientific Affairs at the time this work was performed; APK, ECH, XLX, SS, PA, BZ, PR, and YZ are employees of Janssen Research & Development; and MS is an employee of Janssen Global Services—these authors own stock or stock options in Johnson & Johnson. Address correspondence to Dr. P. Rahman, 154 LeMarchant Road, St. Clare's Mercy Hospital, St. John's, NL A1C 5B8, Canada. Email: prahman@mun.ca. Accepted for publication April 20, 2021.
Yanli Zhuang
This study was sponsored by Janssen Research & Development. P. Rahman, MD, Memorial University of Newfoundland, St. John's, Newfoundland, Canada; C.T. Ritchlin, MD, MPH, University of Rochester, Rochester, New York, USA; P.S. Helliwell, PhD, University of Leeds, Leeds, UK; W.H. Boehncke, MD, Geneva University Hospitals, Geneva, Switzerland; P.J. Mease, MD, Swedish Medical Center/Providence St Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A.B. Gottlieb, MD, PhD, Icahn Medical School at Mount Sinai, New York, New York, USA; S. Kafka, MD, Janssen Scientific Affairs, Horsham, Pennsylvania, USA; A.P. Kollmeier, MD, X.L. Xu, PhD, Janssen Research & Development, San Diego, California, USA; E.C. Hsia, MD, Janssen Research & Development, Spring House, Pennsylvania, USA, and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; M. Shawi, PhD, Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, Pennsylvania, USA; S. Sheng, PhD, P. Agarwal, PhD, B. Zhou, PhD, P. Ramachandran, MD, MPH, Y. Zhuang, PhD, Janssen Research & Development, Spring House, Pennsylvania, USA; I.B. McInnes, MD, PhD, University of Glasgow, Glasgow, UK. CTR has received research support from AbbVie, Amgen, and UCB, and consultant fees from AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB. PR has received research support from Janssen and Novartis; consultant fees from Abbott, AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB; and speakers bureau support from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. PSH has received consulting fees from Eli Lilly and fees for educational services from Amgen, Janssen, Novartis, and Pfizer. WHB has received research support from Pfizer and consulting fees and speaker bureau support from AbbVie, Almirall, Celgene, Janssen, LEO Pharma, Eli Lilly, Novartis, and UCB. IBM has received research support from AstraZeneca, BMS, Celgene, Janssen, Eli Lilly, Novartis, and UCB, and consultant fees from AbbVie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Gilead, Janssen, Novartis, and UCB. ABG has received research support from Boehringer Ingelheim, Incyte, Janssen, Novartis, Sun Pharmaceutical Industries, UCB, and XBiotech; honoraria from Amgen, BMS, Celgene, Janssen, LEO Pharma, Novartis, and UCB Pharma; consultant fees from AnaptysBio, Avotres, Boehringer Ingelheim, Incyte, Lilly ICOS, Novartis, Pfizer, and Sun Pharmaceutical Industries; and stock options from XBiotech. PJM has received research support, consulting fees, and speaker bureau support from AbbVie, Amgen, BMS, Celgene, Crescendo Bioscience, Genentech, Janssen, Eli Lilly, Merck, Novartis, Pfizer, and UCB. SK was an employee of Janssen Scientific Affairs at the time this work was performed; APK, ECH, XLX, SS, PA, BZ, PR, and YZ are employees of Janssen Research & Development; and MS is an employee of Janssen Global Services—these authors own stock or stock options in Johnson & Johnson. Address correspondence to Dr. P. Rahman, 154 LeMarchant Road, St. Clare's Mercy Hospital, St. John's, NL A1C 5B8, Canada. Email: prahman@mun.ca. Accepted for publication April 20, 2021.
Iain B. McInnes
This study was sponsored by Janssen Research & Development. P. Rahman, MD, Memorial University of Newfoundland, St. John's, Newfoundland, Canada; C.T. Ritchlin, MD, MPH, University of Rochester, Rochester, New York, USA; P.S. Helliwell, PhD, University of Leeds, Leeds, UK; W.H. Boehncke, MD, Geneva University Hospitals, Geneva, Switzerland; P.J. Mease, MD, Swedish Medical Center/Providence St Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A.B. Gottlieb, MD, PhD, Icahn Medical School at Mount Sinai, New York, New York, USA; S. Kafka, MD, Janssen Scientific Affairs, Horsham, Pennsylvania, USA; A.P. Kollmeier, MD, X.L. Xu, PhD, Janssen Research & Development, San Diego, California, USA; E.C. Hsia, MD, Janssen Research & Development, Spring House, Pennsylvania, USA, and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; M. Shawi, PhD, Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, Pennsylvania, USA; S. Sheng, PhD, P. Agarwal, PhD, B. Zhou, PhD, P. Ramachandran, MD, MPH, Y. Zhuang, PhD, Janssen Research & Development, Spring House, Pennsylvania, USA; I.B. McInnes, MD, PhD, University of Glasgow, Glasgow, UK. CTR has received research support from AbbVie, Amgen, and UCB, and consultant fees from AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB. PR has received research support from Janssen and Novartis; consultant fees from Abbott, AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB; and speakers bureau support from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. PSH has received consulting fees from Eli Lilly and fees for educational services from Amgen, Janssen, Novartis, and Pfizer. WHB has received research support from Pfizer and consulting fees and speaker bureau support from AbbVie, Almirall, Celgene, Janssen, LEO Pharma, Eli Lilly, Novartis, and UCB. IBM has received research support from AstraZeneca, BMS, Celgene, Janssen, Eli Lilly, Novartis, and UCB, and consultant fees from AbbVie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Gilead, Janssen, Novartis, and UCB. ABG has received research support from Boehringer Ingelheim, Incyte, Janssen, Novartis, Sun Pharmaceutical Industries, UCB, and XBiotech; honoraria from Amgen, BMS, Celgene, Janssen, LEO Pharma, Novartis, and UCB Pharma; consultant fees from AnaptysBio, Avotres, Boehringer Ingelheim, Incyte, Lilly ICOS, Novartis, Pfizer, and Sun Pharmaceutical Industries; and stock options from XBiotech. PJM has received research support, consulting fees, and speaker bureau support from AbbVie, Amgen, BMS, Celgene, Crescendo Bioscience, Genentech, Janssen, Eli Lilly, Merck, Novartis, Pfizer, and UCB. SK was an employee of Janssen Scientific Affairs at the time this work was performed; APK, ECH, XLX, SS, PA, BZ, PR, and YZ are employees of Janssen Research & Development; and MS is an employee of Janssen Global Services—these authors own stock or stock options in Johnson & Johnson. Address correspondence to Dr. P. Rahman, 154 LeMarchant Road, St. Clare's Mercy Hospital, St. John's, NL A1C 5B8, Canada. Email: prahman@mun.ca. Accepted for publication April 20, 2021.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic Arthritis
Proton Rahman, Christopher T. Ritchlin, Philip S. Helliwell, Wolf-Henning Boehncke, Philip J. Mease, Alice B. Gottlieb, Shelly Kafka, Alexa P. Kollmeier, Elizabeth C. Hsia, Xie L. Xu, May Shawi, Shihong Sheng, Prasheen Agarwal, Bei Zhou, Paraneedharan Ramachandran, Yanli Zhuang, Iain B. McInnes
The Journal of Rheumatology May 2021, jrheum.201532; DOI: 10.3899/jrheum.201532
Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic Arthritis
Proton Rahman, Christopher T. Ritchlin, Philip S. Helliwell, Wolf-Henning Boehncke, Philip J. Mease, Alice B. Gottlieb, Shelly Kafka, Alexa P. Kollmeier, Elizabeth C. Hsia, Xie L. Xu, May Shawi, Shihong Sheng, Prasheen Agarwal, Bei Zhou, Paraneedharan Ramachandran, Yanli Zhuang, Iain B. McInnes
The Journal of Rheumatology May 2021, jrheum.201532; DOI: 10.3899/jrheum.201532